Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Cadrenal Therapeutics, Inc. Common Stock（CVKD）的公开报告公司资料与已保存市场数据，附来源与数据时间。已保存数据并非实时行情。
公司概况
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. The Company's pipeline includes CAD-1005, tecarfarin, and frunexian. CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression.
公司资料
- 板块
- Health Care
- 行业
- Pharmaceutical Preparations
- 市值
- $3.6M
- 注册国家/地区
- United States
- 公司官网
- www.cadrenal.com
- 交易所
- NASDAQ
已保存报价
已保存快照，并非实时行情。使用前请核对行情时间。
- 已报告价格
- $0.9998
- 已报告涨跌幅
- +0.28%
- 已报告成交量
- 344,202
- 最新行情时间
空头持仓量
- 已报告空头持仓量
- 118,800 股
- 结算日期
- 来源
- Nasdaq
交易所公布的指定结算日空头持仓量，并非实时空头头寸。
研究这家公司
FennEdge 整理 SEC 文件与已报告市场数据。登录后可使用更多研究功能和私人交易信息。
登录后继续